HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.108.057232v1 50/Suppl_1/89S    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krause, B. J. Articles by zum Büschenfelde, C. M. Search for Related Content PubMed PubMed Citation Articles by Krause, B. J. Articles by zum Büschenfelde, C. M.

¹⁸F-FDG PET and ¹⁸F-FDG PET/CT for Assessing Response to Therapy in Esophageal Cancer

¹ Department of Nuclear Medicine, Technische Universität München, Munich, Germany; ² Department of Radiology, Technische Universität München, Munich, Germany; and ³ Department of Internal Medicine, Technische Universität München, Munich, Germany

Correspondence: For correspondence or reprints contact: Bernd Joachim Krause, Department of Nuclear Medicine, Klinikum rechts der Isar Technische Universität München, Ismaninger Str. 22, 81675 München, Germany. E-mail: Bernd-Joachim.Krause{at}tum.de

In patients with locally advanced esophageal cancer, preoperative chemotherapy or chemoradiotherapy has been shown to improve outcome with respect to survival. Patients who respond to induction therapy have a significantly improved survival, compared with patients who do not respond to the therapy. However, surrogate markers that predict response or prognosis—especially early in the course of therapy—are not available in clinical routine. In patients with esophageal cancer, PET with the glucose analog ¹⁸F-FDG can be used for assessing response to therapy. Therapy response can be assessed with ¹⁸F-FDG PET and ¹⁸F-FDG PET/CT late, that is, after completion of therapy, and early in the course of therapy. In adenocarcinomas of the esophagogastric junction, ¹⁸F-FDG has been established and validated in several studies as a surrogate marker that allows prediction of response and prognosis, whereas in other studies ¹⁸F-FDG PET was not predictive of response and prognosis. The MUNICON study was an initial unicenter trial showing that a PET-guided treatment algorithm was feasible in patients with adenocarcinomas of the esophagogastric junction. The results of this study are important toward individualization of multimodal treatment. The use of ¹⁸F-FDG PET and PET/CT for therapy monitoring in esophageal cancer is the subject of intense discussion, underlining the need for randomized multicenter studies. From a methodologic point of view, the most important issue in therapy monitoring using ¹⁸F-FDG PET and PET/CT is the standardization of patient preparation, data acquisition and processing, and data interpretation, especially for prospective randomized multicenter studies. In conclusion, single-center studies investigating response assessment in patients with esophageal cancer have provided promising results. In the future, prospective randomized multicenter trials will have to be performed and research will address new imaging probes and innovative therapy regimens.

Key Words: esophageal cancer • ¹⁸F-FDG • PET • PET/CT • therapy response

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.

This article has been cited by other articles:

				W. A. Weber Assessing Tumor Response to Therapy J. Nucl. Med., May 1, 2009; 50(Suppl_1): 1S - 10S. [Abstract] [Full Text] [PDF]